Clinical Trials Directory

Trials / Unknown

UnknownNCT06201780

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
All
Age
15 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release . Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions. The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum levels of Janus Kinase 1and 2assessment of serum levels of Janus Kinase 1and 2 by ELISA

Timeline

Start date
2023-12-15
Primary completion
2024-12-10
Completion
2024-12-10
First posted
2024-01-11
Last updated
2024-01-11

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06201780. Inclusion in this directory is not an endorsement.